10x Genomics
85 hedge funds and large institutions have $2.35B invested in 10x Genomics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 27 closing their positions.
120% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $2.68M
109% more capital invested
Capital invested by funds: $1.13B → $2.35B (+$1.22B)
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14.6% more ownership
Funds ownership: 38.56% → 53.16% (+15%)
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
8% less funds holding
Funds holding: 92 → 85 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$40.9M |
| 2 |
Morgan Stanley
New York
|
+$38.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.9M |
| 2 |
BlackRock
New York
|
-$27M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.56M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$6.42M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.92M |
TXG Hedge Fund Activity: Q4 2019 in Review
85 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2019, worth a combined $2.35B — up 109% from $1.13B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of TXG and 26 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 26 added.
The largest buyer was AllianceBernstein, adding an estimated $40.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $29.9M.
- 85 institutional investors held 10x Genomics (TXG) as of Q4 2019, down from 92 in Q3 2019.
- Funds reported $2.35B of 10x Genomics stock for Q4 2019, up 109% quarter-over-quarter.
- 26 funds opened new 10x Genomics positions in Q4 2019 and 27 closed out, a net change of -1 holder.
- The largest 10x Genomics buyer in Q4 2019 was AllianceBernstein, an estimated $40.9M added.
- The largest 10x Genomics seller in Q4 2019 was T. Rowe Price Associates, an estimated $29.9M sold.
Based on aggregated 13F filings for Q4 2019.